公开(公告)号：KR1020130058225A

公开(公告)日：2013-06-04

申请号：KR1020110124122

申请日：2011-11-25

Applicant: 한국과학기술연구원

Inventor： 추현아 ,  김영재 ,  김지연 ,  염미영

IPC: C07D241/04 ,  A61K31/496 ,  A61K31/495 ,  A61K31/065

Abstract: PURPOSE: A biphenyl derivative or a pharmaceutically acceptable salt thereof is provided to ensure excellent activity to 5-HT7 serotonin receptor and to be used as a preventive and therapeutic agent for depression, migraine, anxiety, pain especially inflammatory pain and neuropathy pain, bio rhythm, sleep, smooth muscle related diseases. CONSTITUTION: A biphenyl derivative is denoted by chemical formula 2. The biphenyl derivative has a structure of chemical formula 4 or 5. A pharmaceutical composition for preventing or treating diseases contains the biphenyl derivative or a pharmaceutically acceptable salt thereof. A method for preparing the biphenyl derivative of chemical formula 2 comprises: a step of performing Suzuki coupling of aryl boronic acid of chemical formula 6 and bromobenzene aldehyde of chemical formula 7 to prepare a biphenyl aldehyde intermediate of chemical formula 8; and a step of performing reductive amination of the biphenyl aldehyde intermediate with arylpiperazine of chemical formula 9.

Abstract translation: 目的：提供联苯衍生物或其药学上可接受的盐，以确保对5-HT7血清素受体的优异活性，并用作抑郁症，偏头痛，焦虑症，疼痛，特别是炎性疼痛和神经病疼痛，生物节律的预防和治疗剂 ，睡眠，平滑肌相关疾病。 构成：联苯衍生物由化学式2表示。联苯衍生物具有化学式4或5的结构。用于预防或治疗疾病的药物组合物含有联苯衍生物或其药学上可接受的盐。 制备化学式2的联苯衍生物的方法包括：进行化学式6的芳基硼酸和化学式7的溴苯醛的Suzuki偶联以制备化学式8的联苯醛中间体的步骤; 以及用化学式9的芳基哌嗪进行联苯醛中间体的还原胺化的步骤。

公开(公告)号：KR101616026B1

公开(公告)日：2016-04-28

申请号：KR1020140101183

申请日：2014-08-06

Applicant: 한국과학기술연구원

Inventor： 최기현 ,  박미리 ,  성진모 ,  김지연

IPC: C12N5/10 ,  C12N5/071 ,  C12N15/09 ,  C12Q1/04

Abstract: 본발명은 CLC-Ka 채널을코딩하는유전자, Barttin(Y98A)를코딩하는유전자및 형광단백질을코딩하는유전자를포함하는플라스미드로형질전환시킨세포주에관한것으로서, 상기 CLC-Ka 채널및 Barttin(Y98A)는 N-말단또는 C-말단에에피토프태그되어있고, 상기형광단백질은할라이드이온에노란색으로반응하는것을특징으로하고, 상기 CLC-Ka 채널, Barttin(Y98A) 및형광단백질을안정적으로발현하는것을특징으로한다. 또한, 테트라사이클린유도에의해발현되는유도안정적발현시스템을가지며, 세포기반형광이미징을이용한고효율검색에활용할수 있으며, CLC-Ka 채널과 Barttin(Y98A)를안정적으로발현함으로써 CLC-Ka 채널과 Barttin이관여하고있는세포내 신호전달과정연구에이용이가능함은물론, 본발명에따른세포주를이용한 CLC-Ka 채널작용기작에대한분자수준의연구, 생리학적기능연구, 저나트륨혈증등 CLC-Ka 채널과관련된신장및 심장질환의예방및 치료제개발에널리활용될수 있다.